Unwrapping the UK medtech market this festive season reveals an NHS undergoing rapid change. It's a puzzle box. On the one hand, there are tidings of great joy: the MHRA is establishing new early access pathways to accelerate the adoption of innovative medical devices. At the same time, NICE is completely transforming its HealthTech programme with the specific aim of driving more technology into the NHS, suggesting innovation is welcome.
But this gift comes with assembly instructions. The NHS 10-Year Plan and subsequent Medium Term Framework have fundamentally changed the landscape. With the NHS operating through local Integrated Care Systems (ICSs) , which are themselves rolling out new neighbourhood-level teams, a 'one size fits all' approach won’t work with the new directives and priorities. Today, success demands local knowledge, a relentless focus on value for money in patient pathways, and a stocking stuffed with real-world evidence.
For a medtech company, especially one new to the UK, how can you successfully navigate the UK market? An expert, on-the-ground outsourced team is one resource that could deliver all your festive wishes.
The market is moving faster than Santa’s sleigh on Christmas Eve, but building a specialist team from scratch, including recruiting, training, managing HR, and enrolling staff in a pension scheme, is a slow and costly process. An outsourced team provides an immediate UK footprint. It allows you to deploy a fully compliant, specialist team in weeks, not months, ensuring you don't miss the window of opportunity that new government and NHS policies are opening up.
An instant team is only valuable if it has the right expertise. The NHS national goals are set (the 'what'), but how they are delivered is largely left to local systems. This means a pitch that works for one ICB could fail in another, if it doesn’t address the specifics of that local area. You need a team that already has local knowledge, understands the new budget holders, and can speak the language of strategic commissioning, which focuses on outcomes, not just activity.
The NHS is stretched and focused on operational pressures and productivity, so a product-led pitch runs the risk of falling flat very quickly. Instead, medtech companies need to understand the patient pathways associated with their product and be an NHS partner who can help co-produce solutions. Outsourcing allows you to build a bespoke team with the specific skills your technology requires, such as Clinical Educators who can manage device implementation, support pathway redesign, and provide the training necessary for your technology to deliver on its promises.
Both local commissioners and national bodies are now almost singularly focused on real-world evidence (RWE). NICE’s new "Early Use" assessment pathway is built entirely around evidence generation plans. A deployed field team could act as an engine to generate this data. It can manage a pilot in one area and produce a replication model that allows other local systems to adopt the innovation with confidence and at scale. This isn't just for launch; NICE's "Existing Use" reviews mean even established technologies need to continuously prove their value.
A core plank of all NHS strategy is the shift from "analogue to digital", and the NHS App is now the "front door” for patients. A specialist outsourced Digital Health Team understands this ecosystem and how to integrate with NHS systems. They can support platform adoption by focusing on interoperability, ensuring your solution fits seamlessly into the patient journey the NHS is trying to build.
Your leadership team's time is precious. It is best spent on global strategy and innovation, rather than on the logistics of UK payroll, fleet management, or HR. An outsourced model handles all these operational burdens. While others are getting tangled in employment law and administration, your expert team is already out in the field, delivering value from day one.
In the current NHS climate, achieving adoption requires a deep understanding of local variation, new commissioning models, and evidence of value.
A flexible, outsourced team is the most effective and rapid way to secure this expertise. It provides the specialist knowledge needed to navigate the system, align with priorities, and demonstrate actual value to the NHS.
CHASE has helped medtech organisations launch and succeed in the UK for over 25 years. We build, employ, and manage bespoke teams with the specific skills your technology requires, accelerating your path to adoption.
Explore our latest thinking, event updates and industry insights to stay informed.

Q4 is a challenge for pharma and medtech field sales teams with limited access to NHS key decision makers for value- based chats and deferred product adoption.

Discover 9 key trends shaping outsourced field teams in pharma and medtech for 2025, as they adapt to new NHS and healthcare sector challenges and demands.
.avif)
Learn how businesses impacted by the Employment Rights Bill can use outsourcing to reduce risk, save costs and enhance workforce management in healthcare.